Changes in selenoprotein P in substantia nigra and putamen in Parkinson's disease

Journal of Parkinson's Disease

Volumn 2, Issue 2, 2012, Pages 115-126

  Bellinger, Frederick P ^a   Raman, Arjun V ^a   Rueli, Rachel H ^a   Bellinger, Miyoko T ^a   Dewing, Andrea S ^a   Seale, Lucia A ^a   Andres, Marilou A ^b   Uyehara Lock, Jane H ^a   White, Lon R ^c   Ross, G Webster ^d   Berry, Marla J ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Chaminade University   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

dopamine; glutathione peroxidase; GPX4; Lewy bodies; Parkinson's disease; presynaptic terminals; putamen; Selenium; selenoprotein P; selenoproteins; striatum; substantia nigra

Indexed keywords

PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; SELENOPROTEIN P;

ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CADAVER; CELL DENSITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; MESENCEPHALON; NERVE ENDING; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PUTAMEN; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ASIAN AMERICANS; GLUTATHIONE PEROXIDASE; HAWAII; HUMANS; MALE; PARKINSON DISEASE; PUTAMEN; SELENOPROTEIN P; STEREOTAXIC TECHNIQUES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84864707345     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2012-11052     Document Type: Article

References (35)

1. Chinta SJ, & Andersen JK (2005) Dopaminergic neurons. Int J Biochem Cell Biol, 37, 942-946.
2. Iversen SD, & Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci, 30, 188-193.
3. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci, 991, 1-14.
4. Hatfield DL, Carlson BA, Xu XM, Mix H, & Gladyshev VN (2006) Selenocysteine incorporation machinery and the role of selenoproteins in development and health. Prog Nucleic Acid Res Mol Biol, 81, 97-142.
5. Labunskyy VM, Hatfield DL, & Gladyshev VN (2007) The Sep 15 protein family: Roles in disulfide bond formation and quality control in the endoplasmic reticulum. IUBMB Life, 59, 1-5.
6. Kim HY, & Gladyshev VN (2007) Methionine sulfoxide reductases: Selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem J, 407, 321-329.
7. Chen J, & Berry MJ (2003) Selenium and selenoproteins in the brain and brain diseases. J Neurochem, 86, 1-12.
8. Zeevalk GD, Razmpour R, & Bernard LP. (2008) Glutathione and Parkinson's disease: Is this the elephant in the room? Biomed Pharmacother, 62, 236-249.
9. Ambani LM, Van Woert MH, & Murphy S (1975) Brain peroxidase and catalase in Parkinson disease. Arch Neurol, 32, 114-118.
10. Power JH, & Blumbergs PC (2009) Cellular glutathione peroxidase in human brain: Cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol, 117, 63-73.
11. van der Brug MP, Blackinton J, Chandran J, Hao LY, Lal A, Mazan-Mamczarz K, Martindale J, Xie C, Ahmad R, Thomas KJ, Beilina A, Gibbs JR, Ding J, Myers AJ, Zhan M, Cai H, Bonini NM, Gorospe M,&CooksonMR(2008)RNAbinding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A, 105, 10244-10249.
12. Blackinton J, Kumaran R, van der Brug MP, Ahmad R, Olson L, Galter D, Lees A, Bandopadhyay R,&CooksonMR(2009) Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett, 452, 8-11.
13. Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, Manning-Bog AB, Berry MJ, White LR, & Ross GW (2011) Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. Mol Neurodegener, 6, 8.
14. Burk RF, & Hill KE (2005) Selenoprotein P: An extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr, 25, 215-235.
15. Scharpf M, Schweizer U, Arzberger T, Roggendorf W, Schomburg L, & Kohrle J (2007) Neuronal and ependymal expression of selenoprotein P in the human brain. J Neural Transm, 114, 877-884.
16. Schweizer U, Brauer AU, Kohrle J, Nitsch R, & Savaskan NE (2004) Selenium and brain function: A poorly recognized liaison. Brain Res Brain Res Rev, 45, 164-178.
17. Bellinger FP, He QP, Bellinger MT, Lin Y, Raman AV,White LR, & Berry MJ (2008) Association of selenoprotein p with Alzheimer's pathology in human cortex. J Alzheimers Dis, 15, 465-472.
18. White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C,&Curb JD (1996) Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA, 276, 955-960.
19. Squires JE, Stoytchev I, Forry EP, & Berry MJ (2007) SBP2 binding affinity is a major determinant in differential selenoprotein mRNA translation and sensitivity to nonsensemediated decay. Mol Cell Biol, 27, 7848-7855.
20. Mouton PR, Long JM, Lei DL, Howard V, Jucker M, Calhoun ME, & Ingram DK (2002) Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res, 956, 30-35.
21. Steinbrenner H, Alili L, Bilgic E, Sies H, & Brenneisen P (2006) Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med, 40, 1513-1523.
22. Steinbrenner H, Alili L, Stuhlmann D, Sies H, & Brenneisen P (2007) Post-translational processing of selenoprotein P: Implications of glycosylation for its utilisation by target cells. Biol Chem, 388, 1043-1051.
23. Hill KE, Chittum HS, Lyons PR, Boeglin ME, & Burk RF (1996) Effect of selenium on selenoprotein P expression in cultured liver cells. Biochim Biophys Acta, 1313, 29-34.
24. Hoefig CS, Renko K, Kohrle J, Birringer M, & Schomburg L (2011) Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. J Nutr Biochem, 22, 945-955.
25. Mouton PR (2002) Principles and Practices of Unbiased Stereology: An Introduction for Bioscientists, Baltimore and London, pp. 97-99.
26. Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, Hardman J, Launer L, Masaki K, Tanner CM, & White LR (2004) Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol, 56, 532-539.
27. Lucking CB, & Brice A (2000) Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci, 57, 1894-1908.
28. Burk RF, Hill KE, Olson GE, Weeber EJ, Motley AK, Winfrey VP, & Austin LM (2007) Deletion of apolipoprotein E receptor-2 in mice lowers brain selenium and causes severe neurological dysfunction and death when a low-selenium diet is fed. J Neurosci, 27, 6207-6211.
29. Olson GE, Winfrey VP, Nagdas SK, Hill KE, & Burk RF (2007) Apolipoprotein E receptor-2 (ApoER2) mediates selenium uptake from selenoprotein P by the mouse testis. J Biol Chem, 282, 12290-12297.
30. Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, & Herz J (2002) Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem, 277, 39944-39952.
31. Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li WP, Adelmann G, Frotscher M, Hammer RE, & Herz J (2005) Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron, 47, 567-579.
32. Johnson KM, & Jeng YJ (1991) Pharmacological evidence for N-methyl-D-aspartate receptors on nigrostriatal dopaminergic nerve terminals. Can J Physiol Pharmacol, 69, 1416-1421.
33. Krebs MO, Desce JM, Kemel ML, Gauchy C, Godeheu G, Cheramy A, & Glowinski J (1991) Glutamatergic control of dopamine release in the rat striatum: Evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem, 56, 81-85.
34. Wang JK (1991) Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes. J Neurochem, 57, 819-822.
35. Peters MM, Hill KE, Burk RF, & Weeber EJ (2006) Altered hippocampus synaptic function in selenoprotein P deficient mice. Mol Neurodegener, 1, 12.79-86